Form 4: Akero Therapeutics COO Jonathan Young Reports Stock Transactions

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported the acquisition of shares through the company's employee stock purchase plan and the sale of shares under a pre-arranged trading plan.

Summary

• On June 28, 2024, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, acquired 1,064 shares of common stock through the company's 2019 Employee Stock Purchase Plan at a price of $19.941 per share.
• These shares were purchased at 85% of the closing price of Akero's common stock on that date.
• On July 1, 2024, Young sold 5,000 shares of common stock at a weighted-average price of $23.404, with prices ranging from $23.185 to $23.680.
• These transactions were executed under a Rule 10b5-1 trading plan established on December 27, 2023.
• Young also indirectly owns 20,000 shares each through three irrevocable trusts (EA, CM, and JL) for the benefit of his children, for which his spouse is the trustee, and he disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions appear to be routine and conducted under a pre-arranged trading plan. The ESPP purchase is a positive, while the sale is a standard practice.

Positives

• The acquisition of shares through the employee stock purchase plan could be seen as a positive signal of confidence in the company.
• The execution of the sale was done via a pre-arranged 10b5-1 trading plan.

Negatives

• The sale of 5,000 shares by the COO could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• Executive stock sales can sometimes create uncertainty among investors, even when conducted under pre-arranged plans.
• Changes in beneficial ownership, even if disclaimed, could potentially impact investor sentiment.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's prospects. Rule 10b5-1 plans are commonly used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives in publicly traded companies, including those in the biotechnology sector like Madrigal Pharmaceuticals and Viking Therapeutics, to manage their stock sales in a compliant manner.
• Employee Stock Purchase Plans (ESPPs) are also standard benefits offered by many companies, allowing employees to purchase company stock at a discounted rate, often around 15%, similar to Akero's plan.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into management's views on the company's stock.
• Employees participating in the ESPP benefit from the discounted stock purchase.

Key Dates